ILD-SARDs Registry and Biorepository

Summary

A complex interaction between demographic, environmental and genetic mechanisms impact the onset, severity and outcome of ILD-SARDs through dysregulation of the immune system and lung pro-biotic pathways. Comorbidity and genetic risk indicate that there are overlapping pathogenic mechanisms among SARDs, some of which underlie ILD in different SARDs.

The purpose of this biobank is to study the clinical, pathological, laboratory, and imaging characteristics of SARDs patients with lung involvement. This will help identify as unique features underlying lung involvement in SARDs. In addition, this may lead to the discovery of novel mechanisms of disease and potentially novel targets of treatment for SARDs patients with lung disease.

Conditions

• Interstitial Lung Disease
• Systemic Autoimmune Disease
• Rheumatic Diseases
• Rheumatic Arthritis
• Systemic Sclerosis
• Autoimmune Myositis
• Systemic Lupus Erythematosus
• Usual Interstitial Pneumonia
• Nonspecific Interstitial Pneumonia

Interventions

OTHER

Blood draws

Blood draws will be performed by personnel that are both qualified and authorized by their employer/institution to perform the procedures. The procedures will be performed with standards expected in the context of clinical care. 40 mL (2-3 tbsp) of blood will be drawn in order to collect DNA, RNA, serum and PBMCs. Blood tubes will be sent to the Bank as per the SOP for patient blood sampling and processing. The blood will be processed, centrifuged and stored by a trained laboratory technician.

OTHER

Other biological samples to biobank (skin, lung and muscle biopsies; bronchoalveolar lavage (BAL fluid)

If the patient's medical care or their participation in a research project involves a biopsy or surgery to remove tissue, the tissue not required for diagnosis (excess tissue) or hospital archives will be included in the biobank. This may include healthy tissue as well as tissue affected by the patient's health condition. The Investigators will not conduct extra procedures in order to obtain samples for the sole purpose of this study and will only operate on what's available. These may include blood samples, skin, lung and muscle biopsies, and bronchoalveolar lavage, all of which will be obtained from the pathology department.

OTHER

Clinical data collection

Participant's relevant medical information from medical records, general health questionnaires and clinical assessments. The data includes gender, date of birth, race/ethnicity, habits, height, weight, vital signs, medical history, family history, pregnancy history, imaging data pertinent to ILDs and SARDs, results of routine blood tests, environmental exposures, medication and treatment exposures and adherence, function and quality of life, patient's assessment of their own health, clinical symptoms.

OTHER

Genetic data/DNA/RNA

Results of the DNA or RNA sequencing, conducted for the Biobank and will be made available to future research; possible single nucleotide polymorphism (SNP) assays (including single SNP, low-plex or microarray-based assays).

Sponsors & Collaborators

• McGill University Health Centre/Research Institute of the McGill University Health Centre

  lead OTHER

• McGill University

  collaborator OTHER

Principal Investigators

• Christian Pineau, MD · McGill University Health Centre/Research Institute of the McGill University Health Centre

• Inés Colmegna, MD · McGill University Health Centre/Research Institute of the McGill University Health Centre

• Silvia Vidal, PhD · McGill University/Research Institute of the McGill University Health Centre

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2021-08-24

Primary Completion

2026-08-31

Completion

2026-08-31

Countries

• Canada

Study Locations